$187.74
4.65% yesterday
NYSE, Nov 15, 10:10 pm CET
ISIN
US1598641074
Symbol
CRL

Charles River Laboratories International, Inc. Stock price

$187.74
-6.13 3.16% 1M
-44.82 19.27% 6M
-48.66 20.58% YTD
+0.17 0.09% 1Y
-196.80 51.18% 3Y
+48.67 35.00% 5Y
+124.26 195.75% 10Y
NYSE, Closing price Fri, Nov 15 2024
-9.16 4.65%
ISIN
US1598641074
Symbol
CRL
Sector
Industry

Key metrics

Market capitalization $9.60b
Enterprise Value $12.20b
P/E (TTM) P/E ratio 23.18
EV/FCF (TTM) EV/FCF 21.76
EV/Sales (TTM) EV/Sales 3.00
P/S ratio (TTM) P/S ratio 2.36
P/B ratio (TTM) P/B ratio 2.54
Revenue growth (TTM) Revenue growth -3.67%
Revenue (TTM) Revenue $4.06b
EBIT (operating result TTM) EBIT $611.24m
Free Cash Flow (TTM) Free Cash Flow $560.48m
Cash position $210.49m
EPS (TTM) EPS $8.10
P/E forward 33.80
P/S forward 2.50
EV/Sales forward 3.15
Short interest 4.70%
Show more

Is Charles River Laboratories International, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Charles River Laboratories International, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Charles River Laboratories International, Inc. forecast:

6x Buy
30%
12x Hold
60%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Charles River Laboratories International, Inc. forecast:

Buy
30%
Hold
60%
Sell
10%

Financial data from Charles River Laboratories International, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,061 4,061
4% 4%
100%
- Direct Costs 2,733 2,733
3% 3%
67%
1,328 1,328
5% 5%
33%
- Selling and Administrative Expenses 376 376
14% 14%
9%
- Research and Development Expense - -
-
-
951 951
1% 1%
23%
- Depreciation and Amortization 340 340
9% 9%
8%
EBIT (Operating Income) EBIT 611 611
6% 6%
15%
Net Profit 419 419
12% 12%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Charles River Laboratories International, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Charles River Laboratories International, Inc. Stock News

Neutral
Business Wire
5 days ago
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at UBS and Jefferies Conferences.
Neutral
Seeking Alpha
9 days ago
Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David W...
Positive
Investors Business Daily
9 days ago
Donald Trump's return to the White House is making big winners out of some S&P 500 stocks. The post 12 Stocks Win Big From Trump's White House Victory appeared first on Investor's Business Daily.
More Charles River Laboratories International, Inc. News

Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Head office United States
CEO James Foster
Employees 21,800
Founded 1947
Website www.criver.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today